Metrics as of 10/13/2026, 06:47 PM (Berlin time), refresh in progress.
Aquestive Therapeutics Stock
Aquestive Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Daniel Barber
- Employees
- 147
- Market cap
- $595 M
- IPO
- 25/07/2018
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of…
Aquestive Therapeutics stock: price history
1D
-1.6%
1W
+2.7%
1M
-0.9%
6M
+14.1%
YTD
-26.7%
1Y
-28.9%
2Y
-3.2%
5Y
+28.3%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~5% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Aquestive Therapeutics
Analyst assessment of Aquestive Therapeutics
PRICE TARGET LOW
US$11.00
CONSENSUS
US$11.00
MEDIAN
US$11.00
PRICE TARGET HIGH
US$11.00
0
STRONG BUY
10
BUY
0
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 24/08/2026
Aquestive Therapeutics stock metrics
P/E
-7.29
P/B
-10.47
EV/EBITDA
-9.05
RETURN ON EQUITY
40.4%
NET MARGIN
-165.5%
DEBT/EQUITY
-1.04
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.3%
FLOAT SHARES
114,593,666
AVG. DAILY VOLUME (30D)
2,070,486
Insider transactions (SEC)
Barber Daniel
Barber Daniel
Korczynski Sherry
Korczynski Sherry
Boyd Peter E.
Institutional holders
Comparable stocks
Frequently asked questions about Aquestive Therapeutics stock
What does Aquestive Therapeutics do?
Aquestive Therapeutics, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Daniel Barber, the company employs around 147 people.
The IPO was on 25/07/2018; the stock trades on NASDAQ under the ticker AQST.
What do analysts say about Aquestive Therapeutics stock?
10 analysts rate the stock, the consensus is Buy (as of 24/08/2026).
The average price target is US$11.00, ranging from US$11.00 to US$11.00, with a median of US$11.00.
This is an external assessment, not a statement by Market Jury.
When does Aquestive Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 5% stronger than usual.
Does Aquestive Therapeutics pay a dividend?
No, Aquestive Therapeutics currently does not pay a dividend.
Which stocks are comparable to Aquestive Therapeutics?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences and Amphastar Pharmaceuticals.
How can I get Aquestive Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Aquestive Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.